Teva, Intel collaborate to develop wearable tech & machine learning platform for Huntington disease

Teva Pharmaceutical Industries Ltd., announced a collaboration with Intel Corporation to develop a unique wearable device and machine learning platform for use in Huntington disease (HD). This platform will continuously monitor and analyze key symptoms that impact daily living, in an effort to better understand disease progression and improve treatment evaluation.Teva, working in collaboration with Intel, will deploy this novel technology platform for the first time in a sub-study within the ongoing phase 2 Open-Pride HD Study. As part of this, patients will be asked to use a smartphone and wear a smartwatch equipped with sensing technology that will continuously measure their general functioning and movement. These data will be wirelessly streamed to a cloud-based platform specifically developed by Intel to analyze data from wearable devices. Proprietary algorithms will then…


Link to Full Article: Teva, Intel collaborate to develop wearable tech & machine learning platform for Huntington disease